These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

813 related items for PubMed ID: 18299307

  • 1. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
    Hassan K, Rodriguez LM, Johnson SE, Tadlock S, Heptulla RA.
    Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
    Päivärinta M, Tapanainen P, Veijola R.
    Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A.
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Insulin glargine: a new once-daily basal insulin for the management of type 1 and type 2 diabetes mellitus.
    Lam S.
    Heart Dis; 2003 Jun; 5(3):231-40. PubMed ID: 12783637
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products.
    Bullano MF, Al-Zakwani IS, Fisher MD, Menditto L, Willey VJ.
    Curr Med Res Opin; 2005 Feb; 21(2):291-8. PubMed ID: 15802000
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [New methods in insulin treatment].
    Neuwirth G.
    Orv Hetil; 2005 Jan 16; 146(3):111-6. PubMed ID: 15693442
    [Abstract] [Full Text] [Related]

  • 16. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
    Fischer JS, McLaughlin T, Loza L, Beauchamp R, Schwartz S, Kipnes M.
    Curr Med Res Opin; 2004 Nov 16; 20(11):1703-10. PubMed ID: 15537471
    [Abstract] [Full Text] [Related]

  • 17. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A, Del Prato S, Bue-Valleskey J, Beattie S, Gates J, de la Peña A, Malone J.
    J Diabetes Complications; 2007 Nov 16; 21(1):20-7. PubMed ID: 17189870
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study).
    Danne T, Philotheou A, Goldman D, Guo X, Ping L, Cali A, Johnston P.
    Pediatr Diabetes; 2013 Dec 16; 14(8):593-601. PubMed ID: 23730996
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.